Intellia Therapeutics, Inc. (NTLA) stock
NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/3025% above fair value
$9.70−0.85 (-8.06%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Intellia Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Intellia Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -821.2%. For fiscal 2025 it was -651.7%, against -923.1% the year before. The highest annual figure on record is -195.2% in fiscal 2016.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -651.7% | +271.4 |
| FY2024 | Dec 31, 2024 | -923.1% | +497.4 |
| FY2023 | Dec 31, 2023 | -1420.5% | −541.5 |
| FY2022 | Dec 31, 2022 | -879.0% | −68.7 |
| FY2021 | Dec 31, 2021 | -810.4% | −574.9 |
| FY2020 | Dec 31, 2020 | -235.5% | +11.3 |
| FY2019 | Dec 31, 2019 | -246.8% | +51.8 |
| FY2018 | Dec 31, 2018 | -298.6% | −32.3 |
| FY2017 | Dec 31, 2017 | -266.3% | −71.2 |
| FY2016 | Dec 31, 2016 | -195.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1707.7% | −898.9 |
| Q2 FY2026 | Jun 30, 2026 | -1472.3% | −700.1 |
| Q1 FY2026 | Mar 31, 2026 | -668.1% | +58.5 |
| Q4 FY2025 | Dec 31, 2025 | -428.9% | +631.0 |
| Q3 FY2025 | Sep 30, 2025 | -808.9% | +780.1 |
| Q2 FY2025 | Jun 30, 2025 | -772.2% | +1226.4 |
| Q1 FY2025 | Mar 31, 2025 | -726.6% | −332.6 |
| Q4 FY2024 | Dec 31, 2024 | -1059.9% | +33.4 |
| Q3 FY2024 | Sep 30, 2024 | -1589.0% | −615.5 |
| Q2 FY2024 | Jun 30, 2024 | -1998.6% | −1110.5 |
| Q1 FY2024 | Mar 31, 2024 | -394.0% | +417.1 |
| Q3 FY2023 | Sep 30, 2023 | -1093.3% | −297.8 |
| Q2 FY2023 | Jun 30, 2023 | -973.5% | −272.8 |
| Q1 FY2023 | Mar 31, 2023 | -888.1% | +393.8 |
| Q4 FY2022 | Dec 31, 2022 | -811.1% | −185.5 |
| Q3 FY2022 | Sep 30, 2022 | -795.5% | +203.9 |
| Q2 FY2022 | Jun 30, 2022 | -700.6% | +353.0 |
| Q1 FY2022 | Mar 31, 2022 | -1282.0% | −561.6 |
| Q4 FY2021 | Dec 31, 2021 | -625.6% | +17.3 |
| Q3 FY2021 | Sep 30, 2021 | -999.3% | −872.9 |
| Q2 FY2021 | Jun 30, 2021 | -1053.7% | −850.6 |
| Q1 FY2021 | Mar 31, 2021 | -720.3% | −464.5 |
| Q4 FY2020 | Dec 31, 2020 | -642.9% | −370.7 |
| Q3 FY2020 | Sep 30, 2020 | -126.5% | +112.1 |
| Q2 FY2020 | Jun 30, 2020 | -203.1% | +43.9 |
| Q1 FY2020 | Mar 31, 2020 | -255.9% | −27.7 |
| Q4 FY2019 | Dec 31, 2019 | -272.2% | −9.0 |
| Q3 FY2019 | Sep 30, 2019 | -238.6% | +86.7 |
| Q2 FY2019 | Jun 30, 2019 | -247.0% | +60.4 |
| Q1 FY2019 | Mar 31, 2019 | -228.2% | +72.1 |
| Q4 FY2018 | Dec 31, 2018 | -263.3% | +107.4 |
| Q3 FY2018 | Sep 30, 2018 | -325.3% | −108.3 |
| Q2 FY2018 | Jun 30, 2018 | -307.3% | −36.7 |
| Q1 FY2018 | Mar 31, 2018 | -300.3% | −92.0 |
| Q4 FY2017 | Dec 31, 2017 | -370.7% | – |
| Q3 FY2017 | Sep 30, 2017 | -217.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -270.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -208.3% | – |
See a number that looks wrong?